我国东、中、西部地区医药制造企业研发投入的影响因素研究

发布时间：2018-01-19 08:05

本文关键词： 医药制造企业地区研发投入影响因素因子分析线性回归　出处：《中国药房》2015年04期 　论文类型：期刊论文

【摘要】：目的:为有效增加我国各地区医药制造企业的研发投入提供参考。方法:采用因子分析、线性回归方法,选取平均企业规模、新产品销售收入占比、行业利润、研发人员占比、政府资金资助强度5个指标,构建东、中、西部地区医药制造企业研发投入的影响因素评价体系,分别评价影响其研发投入的关键因素。结果与结论:影响东、中、西部地区医药制造企业研发投入的关键因素各不相同。在3个模型中,政府资金资助强度因素指标系数均较大,表明该指标对各地区医药制造企业研发投入的影响均较显著。研发人员占比、平均企业规模和研发人员占比、平均企业规模指标分别是东、中、西部地区研发投入的关键影响因素。建议各地区医药制造企业抓住各自的关键影响因素,因地制宜,有效提高研发投入。
[Abstract]:Objective: to provide a reference for increasing the R & D investment of pharmaceutical manufacturing enterprises in various regions of China. Methods: factor analysis, linear regression method, average enterprise size, new product sales revenue, and industry profit were adopted. The proportion of R & D personnel and the intensity of government funding are five indexes to construct the evaluation system of the influencing factors of R & D investment of pharmaceutical manufacturing enterprises in the east, middle and west regions. Results and conclusions: the key factors affecting R & D investment of pharmaceutical manufacturing enterprises in the east, middle and west regions are different. In three models. The index coefficient of the intensity of government funding is large, which shows that the impact of this index on the R & D investment of pharmaceutical manufacturing enterprises in different regions is significant. The proportion of R & D personnel, the average enterprise size and R & D personnel share. The average enterprise scale index is the key factors of R & D investment in east, middle and west regions respectively. It is suggested that the pharmaceutical manufacturing enterprises in different regions should grasp their own key influencing factors and improve their R & D investment effectively according to local conditions.
【作者单位】：中国药科大学国际医药商学院;
【分类号】：F426.72
【正文快照】： 《医药工业“十二五”发展规划》中指出,近年来我国医药制造企业得到了飞速发展,有望于2020年成为世界第二大药品市场,但目前仍存在着技术创新能力弱、企业研发投入低等突出矛盾[1]。资金投入不足已成为制约我国创新药物研发的重要不利因素[2]。此外,我国东、中、西部区域间经

【参考文献】